RCS - Brit Utd ProvAscBUPA - Bupa announces CFO Joy Linton to leave in 2021

Carr'sAnnouncement

01/10/2020 08:05

RNS Number : 7735A
  
British Utd Provident Assoc (BUPA)
  
01 October 2020
  
 

The British United Provident Association Limited (Bupa):
 
Bupa announces Group CFO Joy Linton will be leaving in 2021; Martin Potkins becomes Interim Group CFO from 1 December 2020 
 
We are today announcing that Joy Linton, Bupa's Group Chief Financial Officer (CFO), will be leaving Bupa in March 2021 to take a major new appointment in Australia. Martin Potkins, Bupa's Corporate Development Director, becomes Interim Group CFO from 1 December 2020 while the search for a permanent successor takes place. Joy and Martin will work together over the period ensuring a smooth transition.
Joy has been Bupa's Group CFO since 2016. She joined Bupa in 2011 and was Finance and Commercial Director of the Australia and New Zealand Market Unit until she moved to London in 2015. She is returning to Australia to take up the role of CFO at CSL Limited, a global biotechnology company and Australia's largest quoted company by market capitalisation. 
Martin's appointment is subject to regulatory approval. He is currently Bupa's Corporate Development Director and Chairman of Bupa Global's international private medical insurance company based in the Republic of Ireland. He was Bupa's Corporate Controller from 2015 to 2019. Martin has substantial financial experience having previously held senior roles at Resolution, Friends Life, Prudential and Aviva.
Evelyn Bourke, Group CEO said: "We all wish Joy every success in her new role at CSL. I know she and her family are delighted to be returning home to Australia. I want to recognise her significant contribution over nearly ten years at Bupa, including five years as Group CFO. She's been an excellent CFO and Board member, and has been key to Bupa's continued financial strength, including through COVID-19. 
"Having previously been Bupa's Corporate Controller, Martin knows us extremely well. He also brings substantial external experience and finance expertise. I know Joy and Martin will ensure a safe and seamless handover over the coming months."
Joy Linton, Group CFO said: "I've loved my decade at Bupa and it's been a tremendous privilege to serve as Group CFO. However, my family and I are pleased to be able to return to Australia and I'm looking forward to joining the CSL team next year. In the meantime, I'm fully focused on my role at Bupa, and on ensuring a smooth transition."
Notes to editors
·   Joy Linton: Joy became Group CFO in March 2016. She joined Bupa in 2011 as CFO of the Australian Health Insurance business, before becoming Finance and Commercial Director of the Australia and New Zealand Market Unit. She moved to the UK in 2015 and was General Manager of the Health Services business as well as the Group's Interim Chief People Officer. Prior to joining Bupa, she was CFO of National Foods, one of Australia's largest food and beverage companies. She was also a Non-Executive Director of Bega Cheese Ltd, an ASX-200 listed company, serving as Chair of their Audit and Risk Committee. 
·      Martin Potkins: Martin joined Bupa in 2015 as the Group's Corporate Controller. In 2019 he became Corporate Development Director and since 2018 he has been Non-Executive Chairman of Bupa Global DAC, Bupa's authorised international private insurance company based in the Republic of Ireland, as well as serving on the Board of Bupa Arabia. Before joining Bupa, Martin held senior roles at Resolution (Group Financial Controller) and Friends Life (Corporate Development Director). He has also held senior finance roles in Prudential and Aviva. 
 
·      Joy will step down from the Bupa Board in March 2021, when Martin will join the Board.
 
·    An internal and external search is being undertaken for a permanent successor to Joy as Group CFO.
Enquiries
Media
Rupert Gowrley (Corporate Affairs): rupert.gowrley@bupa.com; +44 (0) 7834 624675
Investors
Gareth Evans (Treasury): ir@bupa.com
 
BUPA 1025Z LN
 
About Bupa
Bupa's purpose is helping people live longer, healthier, happier lives. With no shareholders, our customers are our focus. We reinvest profits into providing more and better healthcare for the benefit of current and future customers. 
Health insurance accounts for the major part of our business with 18m customers and contributes 74% of revenue. We operate clinics, dental centres and hospitals in some markets. We run aged care businesses in the UK, Australia, New Zealand and Spain. 
We directly employ around 83,000 people, principally in the UK, Australia, Spain, Chile, Poland, New Zealand, Hong Kong, Turkey, Brazil, the US, Middle East and Ireland. We also have associate businesses in Saudi Arabia and India. 
For more information, visit www.bupa.com
 
About CSL Limited
(ASX:CSL; USOTC:CSLLY) 
CSL is a global biotechnology company with a portfolio of medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. For more information, visit www.csl.com
 
END

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Private Policy.
 
  END
 
 
NRAGUBDGIXGDGGB